Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina

Detalhes bibliográficos
Autor(a) principal: PERES FILHO, Marco Júnio
Data de Publicação: 2010
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFG
Texto Completo: http://repositorio.bc.ufg.br/tede/handle/tde/2090
Resumo: Among manufacturing processes available, direct compression is indicated for OLZ because this drug is moisture sensitive. Before drug developement, preformulation investigations involving physical and chemical properties of drug and excipient combined and separated must be performed. Thus, drug solubility profile, thermal analysis techniques, mainly DSC and TG, and X rays graphics are used to verify drug behavior. The objective of this work was preformulation study of OLZ, drug development and characterization of OLZ tablets to accomplish pharmaceutical equivalence. DSC and TG tests were performed, as well as X rays diffraction and solubility test in different media. Media used in solubility assay were: water; HCl 0,1 mol/L; and USP buffers pH 2.5; pH 4.5; pH 6.8 and pH 7.4. This test duration was 48h. OLZ showed to be more soluble in acidic pH, HCl medium, in which it reached the concentration of 20,62 mg/mL, without saturation. In buffers pH 2.5 and 4.5 saturation solubility was 2,06 mg/mL and 5,19 mg/mL, respectively; in pH 6.8 and pH 7.4 OLZ reached only 221,45 μg/mL and 79,06 μg/mL, respectively. Concentration of OLZ in water was even lower, 48,87 μg/mL. OLZ did not show incompatibility evidence when mixed with corn starch, croscarmellose, crospovidone, dicalcium phosphate anhydrous and dihydrate, magnesium stearate, microcrystalline cellulose PH-101 and PH-102, sodium lauryl sulfate and titanium dioxide. There was solid state interaction with ethylcellulose and opadry YS-1- 7006®, and incompatibility with silicon dioxide and PEG 4000. There was also evidence of interaction in DSC and TG with both types of lactose tested, 22AN® e monohydrate. Lactose monohydrate sample did not confirm interaction by X rays diffraction analysis. However, lactose is not the best choice of diluent to dosage forms containing OLZ, due to indications of Maillard reaction occurrence between referred substances. Olanzapine tablets were obtained, with 2,5 mg of dosage, by direct compression process, due to drug moisture sensitiveness. When microcrystalline cellulose PH-102 was used in formulations as major diluent, physical specifications were reached. It was used together with dicalcium phosphate anhydrous to improve formulation flowability. Coating suspension formulation contained opadry YS-1- 7006®, methocel K4MPR® and titanium dioxide in total concentration of 10%. Though this film coating appropriate drug release profile was reached, as well as pharmaceutical equivalence.
id UFG-2_57328fb63fa5c071f408d071a3a6a0cd
oai_identifier_str oai:repositorio.bc.ufg.br:tde/2090
network_acronym_str UFG-2
network_name_str Repositório Institucional da UFG
repository_id_str
spelling LIMA, Eliana Martinshttp://lattes.cnpq.br/7248774319455970http://lattes.cnpq.br/1672585289858682PERES FILHO, Marco Júnio2014-07-29T16:11:46Z2011-01-112010-06-21PERES FILHO, Marco Júnio. Study of pre-formulation, pharmaceutical development and characterization of solid dosage forms of olanzapine. 2010. 138 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2010.http://repositorio.bc.ufg.br/tede/handle/tde/2090Among manufacturing processes available, direct compression is indicated for OLZ because this drug is moisture sensitive. Before drug developement, preformulation investigations involving physical and chemical properties of drug and excipient combined and separated must be performed. Thus, drug solubility profile, thermal analysis techniques, mainly DSC and TG, and X rays graphics are used to verify drug behavior. The objective of this work was preformulation study of OLZ, drug development and characterization of OLZ tablets to accomplish pharmaceutical equivalence. DSC and TG tests were performed, as well as X rays diffraction and solubility test in different media. Media used in solubility assay were: water; HCl 0,1 mol/L; and USP buffers pH 2.5; pH 4.5; pH 6.8 and pH 7.4. This test duration was 48h. OLZ showed to be more soluble in acidic pH, HCl medium, in which it reached the concentration of 20,62 mg/mL, without saturation. In buffers pH 2.5 and 4.5 saturation solubility was 2,06 mg/mL and 5,19 mg/mL, respectively; in pH 6.8 and pH 7.4 OLZ reached only 221,45 μg/mL and 79,06 μg/mL, respectively. Concentration of OLZ in water was even lower, 48,87 μg/mL. OLZ did not show incompatibility evidence when mixed with corn starch, croscarmellose, crospovidone, dicalcium phosphate anhydrous and dihydrate, magnesium stearate, microcrystalline cellulose PH-101 and PH-102, sodium lauryl sulfate and titanium dioxide. There was solid state interaction with ethylcellulose and opadry YS-1- 7006®, and incompatibility with silicon dioxide and PEG 4000. There was also evidence of interaction in DSC and TG with both types of lactose tested, 22AN® e monohydrate. Lactose monohydrate sample did not confirm interaction by X rays diffraction analysis. However, lactose is not the best choice of diluent to dosage forms containing OLZ, due to indications of Maillard reaction occurrence between referred substances. Olanzapine tablets were obtained, with 2,5 mg of dosage, by direct compression process, due to drug moisture sensitiveness. When microcrystalline cellulose PH-102 was used in formulations as major diluent, physical specifications were reached. It was used together with dicalcium phosphate anhydrous to improve formulation flowability. Coating suspension formulation contained opadry YS-1- 7006®, methocel K4MPR® and titanium dioxide in total concentration of 10%. Though this film coating appropriate drug release profile was reached, as well as pharmaceutical equivalence.Dentre os possíveis processos de produção de formas farmacêuticas sólidas, a compressão direta é indicada para a olanzapina (OLZ) devido à sensibilidade do fármaco à umidade. Ainda antes da formulação, devem ser realizadas investigações de pré-formulação, envolvendo as propriedades físicas e químicas do fármaco e dos excipientes isoladamente e quando combinados. Assim, a determinação do perfil de solubilidade, as técnicas de análise térmica, notadamente DSC e TG, a difração de raios X são usadas para verificar o comportamento do fármaco. O objetivo do trabalho foi o estudo de pré-formulação do fármaco olanzapina, o desenvolvimento farmacotécnico de comprimidos equivalentes ao medicamento referência e a caracterização dos mesmos. Foram feitos ensaios em DSC e TG, difração de raios X e teste de solubilidade em diferentes meios. Os meios utilizados no ensaio de solubilidade foram: água; HCl 0,1 mol/L; e os tampões pH 2,5; pH 4,5; pH 6,8 e pH 7,4. O teste foi executado durante 48h. O fármaco mostrou-se comparativamente mais solúvel em pH ácido, no meio HCl, em que atingiu a concentração de 20,62 mg/mL sem saturação. Nos tampões pH 2,5 e 4,5 a concentração de saturação foi 2,06 mg/mL e 5,19 mg/mL, respectivamente; em pH 6,8 e 7,4 a OLZ atingiu apenas 221,45 μg/mL e 79,06 μg/mL, respectivamente. A concentração final da OLZ em água foi ainda menor, 48,87 μg/mL. A olanzapina não apresentou indícios de incompatibilidade com os excipientes amido de milho, celulose microcristalina PH-101 e PH-102, croscarmelose, crospovidona, dióxido de titânio, estearato de magnésio, fosfato dicálcico anidro e dihidratado e lauril sulfato de sódio. Foi verificada interação no estado sólido com etilcelulose e opadry YS-1-7006®, além de incompatibilidade com o dióxido de silício e o PEG 4000. Há ainda evidências de interação em DSC e TG com os dois tipos de lactose testados, 22AN® e monoidratada. No caso da lactose monoidratada, essa informação não foi confirmada através da difração de raios X. Porém, a lactose não é a melhor opção de diluente para formas farmacêuticas contendo OLZ, devido aos indicativos de que ocorre reação de Maillard entre essas duas substâncias. Foram obtidos comprimidos de OLZ, de dosagem 2,5 mg, pelo processo de compressão direta. Quando a celulose microcristalina PH-102 foi usada em formulações como diluente principal, as especificações físicas foram atingidas. Ela foi empregada em conjunto o fosfato dicálcico anidro para melhorar as propriedades de fluxo da formulação. A suspensão usada no revestimento dos núcleos continha opadry YS-1-7006®, methocel K4MPR® e dióxido de titânio em concentração total de 10%. A partir disso, foi conseguido o perfil de liberação do fármaco que conferiu equivalência farmacêutica em relação ao medicamento referência.Made available in DSpace on 2014-07-29T16:11:46Z (GMT). No. of bitstreams: 1 Marco junio.pdf: 1476076 bytes, checksum: 101c2cff0173a1fc68b6ab8c84454bc2 (MD5) Previous issue date: 2010-06-21application/pdfhttp://repositorio.bc.ufg.br/TEDE/retrieve/3890/Marco%20junio.pdf.jpgporUniversidade Federal de GoiásMestrado em Ciências FarmacêuticasUFGBRCiências da Saúde - FarmáciaolanzapinaDSCTGsolubilidadecomprimidos1.Olanzapina 2.Calorimetria Exploratória Diferencial 3.SolubilidadeolanzapineDSCTGsolubilitytabletsCNPQ::CIENCIAS DA SAUDE::FARMACIAEstudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapinaStudy of pre-formulation, pharmaceutical development and characterization of solid dosage forms of olanzapineinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFGinstname:Universidade Federal de Goiás (UFG)instacron:UFGORIGINALMarco junio.pdfapplication/pdf1476076http://repositorio.bc.ufg.br/tede/bitstreams/486dffed-60ab-45c3-a3b0-91e00bff08df/download101c2cff0173a1fc68b6ab8c84454bc2MD51TEXTMarco junio.pdf.txtMarco junio.pdf.txtExtracted Texttext/plain238265http://repositorio.bc.ufg.br/tede/bitstreams/176b8dca-7f3a-442f-9766-21de3ecfe69d/downloaddeacb5cf4cac81a6f1d445bb2beb6cdbMD52THUMBNAILMarco junio.pdf.jpgMarco junio.pdf.jpgGenerated Thumbnailimage/jpeg1943http://repositorio.bc.ufg.br/tede/bitstreams/e50210ef-c90c-4f11-aa1d-40bdd023fcf5/downloadcc73c4c239a4c332d642ba1e7c7a9fb2MD53tde/20902014-07-30 03:09:10.895open.accessoai:repositorio.bc.ufg.br:tde/2090http://repositorio.bc.ufg.br/tedeRepositório InstitucionalPUBhttp://repositorio.bc.ufg.br/oai/requesttasesdissertacoes.bc@ufg.bropendoar:2014-07-30T06:09:10Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)false
dc.title.por.fl_str_mv Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
dc.title.alternative.eng.fl_str_mv Study of pre-formulation, pharmaceutical development and characterization of solid dosage forms of olanzapine
title Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
spellingShingle Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
PERES FILHO, Marco Júnio
olanzapina
DSC
TG
solubilidade
comprimidos
1.Olanzapina 2.Calorimetria Exploratória Diferencial 3.Solubilidade
olanzapine
DSC
TG
solubility
tablets
CNPQ::CIENCIAS DA SAUDE::FARMACIA
title_short Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
title_full Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
title_fullStr Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
title_full_unstemmed Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
title_sort Estudo de pré-formulação, desenvolvimento farmacotécnico e caracterização de formas farmacêuticas sólidas da olanzapina
author PERES FILHO, Marco Júnio
author_facet PERES FILHO, Marco Júnio
author_role author
dc.contributor.advisor1.fl_str_mv LIMA, Eliana Martins
dc.contributor.advisor1Lattes.fl_str_mv http://lattes.cnpq.br/7248774319455970
dc.contributor.authorLattes.fl_str_mv http://lattes.cnpq.br/1672585289858682
dc.contributor.author.fl_str_mv PERES FILHO, Marco Júnio
contributor_str_mv LIMA, Eliana Martins
dc.subject.por.fl_str_mv olanzapina
DSC
TG
solubilidade
comprimidos
1.Olanzapina 2.Calorimetria Exploratória Diferencial 3.Solubilidade
topic olanzapina
DSC
TG
solubilidade
comprimidos
1.Olanzapina 2.Calorimetria Exploratória Diferencial 3.Solubilidade
olanzapine
DSC
TG
solubility
tablets
CNPQ::CIENCIAS DA SAUDE::FARMACIA
dc.subject.eng.fl_str_mv olanzapine
DSC
TG
solubility
tablets
dc.subject.cnpq.fl_str_mv CNPQ::CIENCIAS DA SAUDE::FARMACIA
description Among manufacturing processes available, direct compression is indicated for OLZ because this drug is moisture sensitive. Before drug developement, preformulation investigations involving physical and chemical properties of drug and excipient combined and separated must be performed. Thus, drug solubility profile, thermal analysis techniques, mainly DSC and TG, and X rays graphics are used to verify drug behavior. The objective of this work was preformulation study of OLZ, drug development and characterization of OLZ tablets to accomplish pharmaceutical equivalence. DSC and TG tests were performed, as well as X rays diffraction and solubility test in different media. Media used in solubility assay were: water; HCl 0,1 mol/L; and USP buffers pH 2.5; pH 4.5; pH 6.8 and pH 7.4. This test duration was 48h. OLZ showed to be more soluble in acidic pH, HCl medium, in which it reached the concentration of 20,62 mg/mL, without saturation. In buffers pH 2.5 and 4.5 saturation solubility was 2,06 mg/mL and 5,19 mg/mL, respectively; in pH 6.8 and pH 7.4 OLZ reached only 221,45 μg/mL and 79,06 μg/mL, respectively. Concentration of OLZ in water was even lower, 48,87 μg/mL. OLZ did not show incompatibility evidence when mixed with corn starch, croscarmellose, crospovidone, dicalcium phosphate anhydrous and dihydrate, magnesium stearate, microcrystalline cellulose PH-101 and PH-102, sodium lauryl sulfate and titanium dioxide. There was solid state interaction with ethylcellulose and opadry YS-1- 7006®, and incompatibility with silicon dioxide and PEG 4000. There was also evidence of interaction in DSC and TG with both types of lactose tested, 22AN® e monohydrate. Lactose monohydrate sample did not confirm interaction by X rays diffraction analysis. However, lactose is not the best choice of diluent to dosage forms containing OLZ, due to indications of Maillard reaction occurrence between referred substances. Olanzapine tablets were obtained, with 2,5 mg of dosage, by direct compression process, due to drug moisture sensitiveness. When microcrystalline cellulose PH-102 was used in formulations as major diluent, physical specifications were reached. It was used together with dicalcium phosphate anhydrous to improve formulation flowability. Coating suspension formulation contained opadry YS-1- 7006®, methocel K4MPR® and titanium dioxide in total concentration of 10%. Though this film coating appropriate drug release profile was reached, as well as pharmaceutical equivalence.
publishDate 2010
dc.date.issued.fl_str_mv 2010-06-21
dc.date.available.fl_str_mv 2011-01-11
dc.date.accessioned.fl_str_mv 2014-07-29T16:11:46Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.citation.fl_str_mv PERES FILHO, Marco Júnio. Study of pre-formulation, pharmaceutical development and characterization of solid dosage forms of olanzapine. 2010. 138 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2010.
dc.identifier.uri.fl_str_mv http://repositorio.bc.ufg.br/tede/handle/tde/2090
identifier_str_mv PERES FILHO, Marco Júnio. Study of pre-formulation, pharmaceutical development and characterization of solid dosage forms of olanzapine. 2010. 138 f. Dissertação (Mestrado em Ciências da Saúde - Farmácia) - Universidade Federal de Goiás, Goiânia, 2010.
url http://repositorio.bc.ufg.br/tede/handle/tde/2090
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Goiás
dc.publisher.program.fl_str_mv Mestrado em Ciências Farmacêuticas
dc.publisher.initials.fl_str_mv UFG
dc.publisher.country.fl_str_mv BR
dc.publisher.department.fl_str_mv Ciências da Saúde - Farmácia
publisher.none.fl_str_mv Universidade Federal de Goiás
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFG
instname:Universidade Federal de Goiás (UFG)
instacron:UFG
instname_str Universidade Federal de Goiás (UFG)
instacron_str UFG
institution UFG
reponame_str Repositório Institucional da UFG
collection Repositório Institucional da UFG
bitstream.url.fl_str_mv http://repositorio.bc.ufg.br/tede/bitstreams/486dffed-60ab-45c3-a3b0-91e00bff08df/download
http://repositorio.bc.ufg.br/tede/bitstreams/176b8dca-7f3a-442f-9766-21de3ecfe69d/download
http://repositorio.bc.ufg.br/tede/bitstreams/e50210ef-c90c-4f11-aa1d-40bdd023fcf5/download
bitstream.checksum.fl_str_mv 101c2cff0173a1fc68b6ab8c84454bc2
deacb5cf4cac81a6f1d445bb2beb6cdb
cc73c4c239a4c332d642ba1e7c7a9fb2
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFG - Universidade Federal de Goiás (UFG)
repository.mail.fl_str_mv tasesdissertacoes.bc@ufg.br
_version_ 1798044337739661312